Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -68.63% is in line with its 3-year average of -74.47%, near the high end of its 3-year range (-273.87%–-47.29%).
2.47% above its 12-month average of -70.37%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -76.41%.
EBITDA MARGIN
-68.63%
EBITDA MARGIN AVG TTM
-70.37%
EBITDA MARGIN AVG 3Y
-74.47%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.47%
CURRENT VS 3Y AVG
+7.84%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Beta Bionics, Inc.
Market Cap
$835.46M
EBITDA Margin
-68.63%
TTM Avg
-70.37%
3Y Avg
-74.47%
5Y Avg
N/A
Market Cap
$844.68M
EBITDA Margin
-37.08%
TTM Avg
-66.80%
3Y Avg
-66.80%
5Y Avg
-66.80%
Market Cap
$827.61M
EBITDA Margin
-1761.78%
TTM Avg
-1761.78%
3Y Avg
-1761.78%
5Y Avg
-1761.78%
Market Cap
$807.78M
EBITDA Margin
-9.31%
TTM Avg
-8.54%
3Y Avg
-46.73%
5Y Avg
-472.39%
Market Cap
$863.62M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$789.11M
EBITDA Margin
18.47%
TTM Avg
18.88%
3Y Avg
13.21%
5Y Avg
14.52%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $835.46M | -68.63% | -70.37% | -74.47% | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $844.68M | -37.08% | -66.80% | -66.80% | -66.80% |
| Alumis Inc. (ALMS)vs › | $827.61M | -1761.78% | -1761.78% | -1761.78% | -1761.78% |
| Jade Biosciences, Inc. (JBIO)vs › | $819.78M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $807.78M | -9.31% | -8.54% | -46.73% | -472.39% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $863.62M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.85M | 23.23% | 25.96% | 33.88% | 36.34% |
| Apnimed, Inc. (APMD)vs › | $804.43M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $789.11M | 18.47% | 18.88% | 13.21% | 14.52% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $783.77M | 12.02% | 14.44% | -4.83% | -238.26% |
Gross Margin
58.3%
EBITDA Margin
-68.6%
Operating Margin
-69.8%
Net Margin
-61.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -76.41% |
| 2026-03-31 | -85.43% |
| 2025-12-31 | -47.29% |
| 2025-09-30 | -60.03% |
| 2025-06-30 | -82.71% |
| 2025-03-31 | -102.26% |
| 2024-12-31 | -61.19% |
| 2024-09-30 | -63.88% |
| 2024-06-30 | -74.49% |
| 2024-03-31 | -68.74% |
| 2023-12-31 | -96.71% |
| 2023-09-30 | -273.87% |
